A PHASE 2 TRIAL OF THE MULTITARGETED KINASE INHIBITOR LENVATINIB (E7080) IN PATIENTS (PTS) WITH RECURRENT GLIOBLASTOMA (GBM) AND DISEASE PROGRESSION FOLLOWING PRIOR BEVACIZUMAB TREATMENT
Publication
, Conference
Reardon, DA; Pan, E; Fan, J; Mink, J; Barboriak, DP; Vredenburgh, JJ; Desjardins, A; Peters, K; O'Brien, JP; Wen, PY
Published in: ANNALS OF ONCOLOGY
September 1, 2012
Duke Scholars
Published In
ANNALS OF ONCOLOGY
ISSN
0923-7534
Publication Date
September 1, 2012
Volume
23
Start / End Page
146 / 146
Location
Vienna, AUSTRIA
Publisher
OXFORD UNIV PRESS
Conference Name
37th Congress of the European-Society-for-Medical-Oncology (ESMO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Reardon, D. A., Pan, E., Fan, J., Mink, J., Barboriak, D. P., Vredenburgh, J. J., … Wen, P. Y. (2012). A PHASE 2 TRIAL OF THE MULTITARGETED KINASE INHIBITOR LENVATINIB (E7080) IN PATIENTS (PTS) WITH RECURRENT GLIOBLASTOMA (GBM) AND DISEASE PROGRESSION FOLLOWING PRIOR BEVACIZUMAB TREATMENT. In ANNALS OF ONCOLOGY (Vol. 23, pp. 146–146). Vienna, AUSTRIA: OXFORD UNIV PRESS.
Reardon, D. A., E. Pan, J. Fan, J. Mink, D. P. Barboriak, J. J. Vredenburgh, A. Desjardins, K. Peters, J. P. O’Brien, and P. Y. Wen. “A PHASE 2 TRIAL OF THE MULTITARGETED KINASE INHIBITOR LENVATINIB (E7080) IN PATIENTS (PTS) WITH RECURRENT GLIOBLASTOMA (GBM) AND DISEASE PROGRESSION FOLLOWING PRIOR BEVACIZUMAB TREATMENT.” In ANNALS OF ONCOLOGY, 23:146–146. OXFORD UNIV PRESS, 2012.
Reardon DA, Pan E, Fan J, Mink J, Barboriak DP, Vredenburgh JJ, et al. A PHASE 2 TRIAL OF THE MULTITARGETED KINASE INHIBITOR LENVATINIB (E7080) IN PATIENTS (PTS) WITH RECURRENT GLIOBLASTOMA (GBM) AND DISEASE PROGRESSION FOLLOWING PRIOR BEVACIZUMAB TREATMENT. In: ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2012. p. 146–146.
Reardon, D. A., et al. “A PHASE 2 TRIAL OF THE MULTITARGETED KINASE INHIBITOR LENVATINIB (E7080) IN PATIENTS (PTS) WITH RECURRENT GLIOBLASTOMA (GBM) AND DISEASE PROGRESSION FOLLOWING PRIOR BEVACIZUMAB TREATMENT.” ANNALS OF ONCOLOGY, vol. 23, OXFORD UNIV PRESS, 2012, pp. 146–146.
Reardon DA, Pan E, Fan J, Mink J, Barboriak DP, Vredenburgh JJ, Desjardins A, Peters K, O’Brien JP, Wen PY. A PHASE 2 TRIAL OF THE MULTITARGETED KINASE INHIBITOR LENVATINIB (E7080) IN PATIENTS (PTS) WITH RECURRENT GLIOBLASTOMA (GBM) AND DISEASE PROGRESSION FOLLOWING PRIOR BEVACIZUMAB TREATMENT. ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2012. p. 146–146.
Published In
ANNALS OF ONCOLOGY
ISSN
0923-7534
Publication Date
September 1, 2012
Volume
23
Start / End Page
146 / 146
Location
Vienna, AUSTRIA
Publisher
OXFORD UNIV PRESS
Conference Name
37th Congress of the European-Society-for-Medical-Oncology (ESMO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis